-- 在Kinaxis (KXS.TO) 今日收盘后公布第一季度业绩前，Stifel Canada将该公司股票的目标价下调45美元至200美元。 分析师Suthan Sukumar维持对该公司“买入”评级，他认为，鉴于全球供应链持续受到关税和地缘政治因素的影响，市场需求前景良好。 Sukumar写道：“人工智能的应用仍处于早期阶段，但我们仍然认为，KXS凭借其广泛的专有实时供应链数据、领域专业知识以及与工作流程的深度集成，在人工智能商业化方面具有独特的优势，并且其客户群高度忠诚，因此该公司今年的股价有望上涨。” Sukumar承认该股“并不便宜”，但他表示，持续的行业利好因素以及2026财年SaaS业务指南中近90%的订单已被现有积压订单覆盖，都预示着该公司未来业绩有望超出预期并上调。 “尽管由于近期软件行业估值倍数略有下降，我们的目标价下调至每股 200 美元，但 KXS 仍然是我们关注的重点股。”
Price: $139.55, Change: $-3.09, Percent Change: -2.17%
Aptiv (APTV) stock sell-off post Q1 results was unwarranted and likely driven by the lower-than-expected Q2 guide and rising cost pressures with 2026 more back-half weighted that appears like a steep ramp, UBS said in a Wednesday research report.While Q2 is impacted by "stranded cost" and Ford Motor (F) volume timing, H2 ramp looks more achievable than optics suggest amid positive developments in China and the non-auto segments, analysts wrote.The company expects positive growth from China in Q2, driven by new programs and normalization of production at key customer, the brokerage stated.Commodity headwinds should abate in H2 as recoveries lag, UBS said.The brokerage said it reiterated its buy rating on the stock and price target of $80 per share.Aptiv shares were up 4% in Wednesday trading.Price: $56.47, Change: $+1.64, Percent Change: +2.99%
Price: $15.79, Change: $-4.34, Percent Change: -21.55%
Ocular Therapeutix (OCUL) is moving closer to a potential US Food and Drug Administration filing for axpaxli, its long-acting treatment for wet age-related macular degeneration, as regulators begin formal discussions on a single-trial approval path, RBC Capital Markets said Tuesday in a report.Management said talks with the FDA are now ongoing, raising the possibility of submitting an application based on the company's successful pivotal study, rather than waiting for a second trial that is due to read out in early 2027, RBC said.The company plans to provide additional regulatory and program updates at an investor day on June 17, RBC said.Ocular continues to target a potential 2027 launch for axpaxli under a single-trial filing strategy, and RBC reiterated its view that the drug has a "positive benefit/risk profile."RBC maintained its rating of outperform, speculative risk, on Ocular stock with a $30 price target.Price: $9.84, Change: $+0.13, Percent Change: +1.29%